Effects and Mechanisms of Checkpoint Inhibitors (CTLA-4, PD-1 and PD-L1 Inhibitors) as New Immunotherapeutic Agents for Bladder Cancer
Journal Title: Üroonkoloji Bülteni - Year 2018, Vol 17, Issue 1
Abstract
Since intravesical Bacillus Calmette-Guerin (BCG) began to be used for bladder cancer, our understanding of the importance of immune mechanisms in bladder cancer has steadily grown. With developments in immunotherapy in recent years, the use of new immunotherapeutic agents for bladder cancer, especially chemotherapy-resistant invasive and metastatic cancers, has opened the way for research in this area. Of these new therapeutic agents, this article reviews studies published on PubMed or listed on the ClinicalTrials.gov website as of December 2017 regarding the effects and mechanisms of action of checkpoint inhibitors [cytotoxic t-lymphocyte associated protein-4, programmed cell death 1 receptor (PD-1) and PD-1 ligand inhibitors] on bladder cancer. Because checkpoint inhibitors were first used for chemotherapy-resistant bladder cancer after identification of positive expression in tumor cells and especially in tumor-infiltrating mononuclear cells, significant objective response rates and survival advantages have been reported. Research continues regarding the use of these agents as first- and second-line treatment for metastatic disease in combination with chemotherapy; their efficacy in neoadjuvant, adjuvant, and bladder-preserving approaches to muscle-invasive bladder cancer (MIBC) disease, and their use in non-muscle-invasize bladder cancer (NMIBC), especially BCG-refractory disease. Depending on the results of these ongoing studies, immunotherapy may direct the treatment of bladder cancer in the future.
Authors and Affiliations
Serdar Çelik, Zekiye Sultan Altun, Safiye Aktaş
Keywords
Related Articles
- EP ID EP379705
- DOI 10.4274/uob.947
- Views 96
- Downloads 0
The Incidence of Prostate Adenocarcinoma in Patients Who Underwent Cystoprostatectomy for Invasive Baldder Cancer and Histopathological Examination
Objective: It was aimed to evaluate the incidence of prostate adenocarcinoma in patients treated by cystoprostatectomy for invasive bladder urothelial carcinoma and to demonstrate the histopathological features of prosta...
Role of Prostate Specific Antigen Density for the Prediction of Radical Therapy Requirement in Localized Prostate Cancer
Objective: Prostate specific antigen (PSA) PSA density (dPSA) is a PSA derivative used for increasing the accuracy of PSA. dPSA is calculated by dividing the prostate volume measured with transrectal ultrasonography by t...
Organ-Preserving Approach in Bladder Cancer: Assessment of the Current Situation
Intravesical bacillus Calmette-Guerin (BCG) therapy is the gold standard treatment option in high-risk non-invasive bladder cancer. However, BCG is a very toxic agent. A significant proportion of patients have BCG intole...
What are the New Developments in Urinary, Serum and Tissue Biomarkers in Prostate Cancer?
Currently the accepted screening tools for prostate cancer are prostate specific antigen (PSA) and rectal examination. PSA is specific to prostate, but not to prostate cancer. Therefore, identifying prostate cancer only...
The Relationship between Bladder Cancer and Epigenetic Alterations
Bladder cancer is one of the most common cancers of urinary system and approximately 70% of the cases are low grade and non-muscle invasive. Because of the histological indicator inadequacy of heterogeneous tumors like b...